On August 26, Sirio Pharma released its half-year report. During the reporting period, the company achieved operating revenue of about RMB 1.111 billion yuan (USD $160 million), with a decrease of 4.6% year-on-year. The company indicated that operating income and net profit declined in the first quarter due to the combined effects of weak domestic consumer demand and recurring pandemics, but improved in the second quarter. The company’s operating income in the second quarter increased by 4.97% and net profit increased by 7.76% year-on-year.
Currently, China has become the second largest and fastest growing market for dietary supplements in the world, so Sirio Pharma remains optimistic about the development of the industry and to maintain good growth in the next five years. Moreover, Sirio Pharma’s third nutritional fudge production line was officially launched in July 2022, with an annual capacity of 1.8 billion capsules. (Source: shuzhengkangxun)
Visit HPA-China’s Information Hub, CLICK HERE